Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancermetastasespriortherapyrandomization
  Phrases that lowered it: bodyperiodeffect ofthe effectproducts
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Minimum age: 45 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 28.1% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 80 (lowers risk) · Who can join
• Sponsor's past trials: 4 (raises risk) · Sponsor's track record
• Keywords listed: 0 (raises risk) · Design
• Drug's FAERS reports marked serious: 93.3% (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 247 (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase II, Dose Finding Study of GTx-758 NCT01393119 · started 2011 · scored riskier than 36% of active trials terminated
• GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer NCT01420861 · started 2011 · scored riskier than 34% of active trials terminated
• Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer NCT01615120 · started 2012 · scored riskier than 87% of active trials completed
• Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer NCT02826772 · started 2016 · scored riskier than 26% of active trials completed
• A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer NCT03450109 · started 2017 · scored riskier than 13% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.